Results 111 to 120 of about 43,229 (277)

Table S2 from Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

, 2023
Michael B. Atkins, F. Stephen Hodi, John A. Thompson, David F. McDermott, Wen‐Jen Hwu, Donald P. Lawrence, Nancy A. Dawson, Deborah J. Wong, Shailender Bhatia, Marihella James, Lokesh Jain, Seth Robey, Xinxin Shu, Blanca Homet Moreno, Rodolfo F. Perini, Toni K. Choueiri, Antoni Ribas   +16 more
openalex   +1 more source

Allogeneic haematopoietic cell transplant in cutaneous T‐cell lymphomas: Recommendations from the EBMT PH&G Committee

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 2, Page 174-184, February 2026.
This EBMT Practice Harmonisation and Guidelines Committee consensus provides practical recommendations for the selection, timing and conduct of allogeneic transplantation in advanced‐stage mycosis fungoides and Sézary syndrome, aiming to optimize outcomes through early multidisciplinary collaboration and evidence‐based decision‐making.
Gandhi Damaj, Adèle de Masson, Peter Dreger, Ali Bazarbachi, Philipp Berning, Rafael F. Duarte, Christopher P. Fox, Emmanuella Guenova, Olivier Hermine, Charalampia Kyriakou, Alina Tanase, Olivier Tournilhac, Wojiech Jurczak, Imke E. Karsten, Stéphanie Nguyen Quoc, Yasmina Serroukh, Federico Stella, Gerald Wulf, Anna Sureda, Evangelia Papadavid, Pablo L. Ortiz‐Romero, Annalisa Ruggeri, Isabel Sánchez‐Ortega, Julia J. Scarisbrick, Ibrahim Yakoub‐Agha, Francesco Onida, Norbert Schmitz   +26 more
wiley   +1 more source

ARE ELDERLY PATIENTS POOR CANDIDATES FOR PEGYLATED INTERFERON PLUS RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C? [PDF]

, 2006
Annarosa Floreani, E. Minola, I. Carderi, Francesco Ferrara, E. Rosa Rizzotto, Vincenzo Baldo   +5 more
openalex   +1 more source

Trends of Advanced Chronic Liver Disease Among 17,711 Persons in Mongolia During Years 2015–2023

Journal of Viral Hepatitis, Volume 33, Issue 2, February 2026.
ABSTRACT Chronic liver diseases cause a significant burden in Asia. This study aims to characterise the pattern and factors associated with advanced chronic liver disease (aCLD) in a large cohort from Mongolia, which has the highest rate of liver cancer globally.
Habiba Kamal, Ganbolor Jargalsaikhan, Sanjaasuren Enkhtaivan, Daniel Bruce, Karin Lindahl, Bekhbold Dashtseren, Tuvshinjargal Ulziibadrakh, Munguntsetseg Batkhuu, Purevjargal Bat‐Ulzii, Sumiya Byambabaatar, Soo Aleman, Naranjargal B. Dashdorj   +11 more
wiley   +1 more source

Dilated cardiomyopathy and hypothyroidism associated with pegylated interferon and ribavirin treatment for chronic hepatitis C: case report and literature review

Brazilian Journal of Infectious Diseases, 2014
Pegylated interferon alpha (Peg IFN-α) in combination with ribavirin is the backbone of treatment in chronic hepatitis C (CHC). Cardiotoxicity due to interferon therapy is rare.
Wenxue Zhao, Fanpu Ji, Shanshan Yu, Zongfang Li, Hong Deng   +4 more
doaj   +1 more source

Treatment of Hepatitis C in Hemodialysis Patients with Pegylated Interferon α-2a as Monotherapy [PDF]

, 2007
Aleksandar Sikole, P. Dzekova, Nexhmi Selja, Magdalena Gaseva, Igor Nikolov, Mustafa Zabzun, Sheriat Muharemi, A Asani, V. Amitov, Sami Mena, Violeta Grunevska, Ljubomir Ivanovski, Momir Polenaković   +12 more
openalex   +1 more source

Some safety aspects of a new russian pegylated interferon-A medication “ALGERON” (phase 1 clinical trial)

RUDN Journal of Medicine, 2014
Treatment of hepatitis C is one of the most acute international healthcare problems. High standard in management of patients with HCV virus is combined therapy with pegylated interferon-a plus ribavirin.
A I Tukach, S B Fitilev, I I Shkrebniova, A V Vozzhaev, V A Yakushev, R A Ivanov, Yu N Lin’kova, T V Chernovskaya   +7 more
doaj  

Early viral kinetics and response to treatment in a hepatitis C virus genotype 5 infected patient

Clinics and Practice, 2011
Genotype 5 hepatitis C has been poorly studied despite its worldwide spread. We have analyzed the early kinetics of genotype 5 hepatitis C virus RNA during pegylated interferon/ribavirin treatment in a 59-year-old man with active liver necroinflammatory ...
Emanuele Durante-Mangoni, Domenico Iossa, Umberto Malgeri   +2 more
doaj   +1 more source

Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection. [PDF]

, 2020
Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin. In an open-label study, we evaluated the safety and efficacy of sofosbuvir plus ribavirin for 12 weeks in children aged ...
Balistreri, William F, Bansal, Sanjay, Brainard, Diana M, Davison, Suzanne, Feiterna-Sperling, Cornelia, Gillis, Lynette A, Gonzalez-Peralta, Regino P, Hsueh, Chia-Hsiang, Indolfi, Giuseppe, Jonas, Maureen M, Kelly, Deidre A, Lin, Chuan-Hao, Massetto, Benedetta, Murray, Karen F, Nightingale, Scott, Parhy, Bandita, Rosenthal, Philip, Schwarz, Kathleen B, Shao, Jiang, Sokal, Etienne M, Wirth, Stefan   +20 more
core  

Pegylated Interferon Lambda for Covid-19

New England Journal of Medicine, 2023
Mingqiang, Wang, Lingling, Tang, Lingtong, Huang   +2 more
openaire   +4 more sources